Apimeds Pharmaceuticals US (APUS) Non-Current Debt (2025 - 2026)
Apimeds Pharmaceuticals US's (APUS) quarterly Non-Current Debt came in at $5.0 million in Q2 2026, up 1900.0% quarter-over-quarter from $250000.0 in Q1 2025.
Powered by 
Analysis
Apimeds Pharmaceuticals US (APUS) Non-Current Debt (2025 - 2026) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has reported Non-Current Debt for 2 consecutive years, with $5.0 million the latest figure, recorded in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 57.30 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 26.25 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 1.99 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 591.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 7.29 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Apimeds Pharmaceuticals US | 3.79 Mn | 3.79 Mn | - | 5.00 Mn |